1. Home
  2. Labeler Index
  3. Boehringer Ingelheim Pharmaceuticals, Inc.
  4. 0597-0197
  5. Product Images: Praxbind

Product Images Praxbind

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Praxbind NDC 0597-0197 by Boehringer Ingelheim Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

figure-1 - figure 1

figure-1 - figure 1

figure-2 - figure 2

figure-2 - figure 2

figure-3 - figure 3

figure-3 - figure 3

figure-4 - figure 4

figure-4 - figure 4

This is a graph showing the time-course of unbound dabigatran levels in a group of healthy subjects after administration of Idarucizumab or Placebo. The various time points, in hours, and related levels of unbound dabigatran are specified on the graph. The lower limit of quantification is 1ng/mL.*

figure-5 - figure 5

figure-5 - figure 5

figure-6 - figure 6

figure-6 - figure 6

The text describes a figure that shows the change in ECT from baseline in patients exposed to Dabigatran, with 487 participants. The figure shows a graph with ECT values on the Y-axis and different time intervals on the X-axis. There are different line plots with data points and percentiles represented in the graph. It is not possible to understand the graph completely without looking at it, but this is the basic information that can be obtained from the text.*

figure-7 - figure 7

figure-7 - figure 7

This is a graph showing the change in aPTT (activated partial thromboplastin time) from baseline in 486 patients exposed to the drug Dabigatran. The graph displays the values at baseline, at 1 hour, 2 hours, 4 hours, 12 hours, and 24 hours post-Idarucizumab. The y-axis ranges from 130 to 140. There are additional details regarding percentiles and upper limits of normal.*

praxbind-label - label 019705

praxbind-label - label 019705

Praxbind® (idarucizumab) Injection is used for intravenous treatment and comes in 2.5g/50 mL single-dose vials. The complete dose of 5g necessitates administering two vials. The product should be kept at 2°C-8°C, and the package should be held away from light until it is time to use it. Please see the package insert for complete prescribing information about dosage and administration. Discard unused portions. No additional information is available.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.